CMS
  • Partnering
  • Contact
    • Contact Information
    • Join Us
  • EN
  • CN
  • About Us
    • CMS Overview
    • Leadership
    • Milestones
    • Social Responsibility
  • Innovation
    • R&D Overview
    • Pipeline
  • Business
    • Business Overview
    • Cardio-cerebrovascular and Gastroenterology
    • Dermatology and Medical Aesthetics
    • Ophthalmology
    • Southeast Asia Business
  • News
    • Company News
    • Partner News
  • Investors
    • Stock Infomation
    • Financial Highlights
    • Information Disclosure
    • Corporate Governance
    • Investor Communication
  • Home
  • About Us
    • CMS Overview
    • Leadership
    • Milestones
    • Social Responsibility
  • Innovation
    • R&D Overview
    • Pipeline
  • Business
    • Business Overview
    • Cardio-cerebrovascular and Gastroenterology
    • Dermatology and Medical Aesthetics
    • Ophthalmology
  • News
    • Company News
    • Partner News
  • Investors
    • Investors
    • Stock Infomation
    • Financial Highlights
    • Information Disclosure
    • Corporate Governance
    • Investor Communication
  • Partnering
  • Contact
    • Contact Information
    • Join Us
  • EN
  • CN
Won the “Best Hong Kong Stock-Connect Company” from Golden Hong Kong Listed Companies
2022-07-08

Won the “Best Hong Kong Stock-Connect Company” from Golden Hong Kong Listed Companies

Honored with three awards including “2019 Top 10 Listed Companies with the Highest Investment Value in China Pharmaceutical Industry”, “Top 100 Innovative Pharmaceutical Enterprises in China” and “Benchmarking Enterprises in Pharmaceutical Industry at the 70th Anniversary of PRC Founding” at the China Healthcare Summit of Entrepreneurs, Scientists and Investors

Honored with three awards including “2019 Top 10 Listed Companies with the Highest Investment Value in China Pharmaceutical Industry”, “Top 100 Innovative Pharmaceutical Enterprises in China” and “Benchmarking Enterprises in Pharmaceutical Industry at the 70th Anniversary of PRC Founding” at the China Healthcare Summit of Entrepreneurs, Scientists and Investors

Tibet Kangzhe was awarded the “Top 20 Private Enterprises of Tibet Autonomous Region”

Tibet Kangzhe was awarded the “Top 20 Private Enterprises of Tibet Autonomous Region”

Obtained the clinical trial notice of Diazepam Nasal Spray from China NMPA

Obtained the clinical trial notice of Diazepam Nasal Spray from China NMPA

Acquired product rights of seven innovative products including Cyclosporine Eye Drops 0.09%, Tildrakizumab Solution for Injection and Paclitaxel Injection Concentrate for Suspension in Mainland China and/or other countries or regions

Acquired product rights of seven innovative products including Cyclosporine Eye Drops 0.09%, Tildrakizumab Solution for Injection and Paclitaxel Injection Concentrate for Suspension in Mainland China and/or other countries or regions

Acquired product rights of 11 generics (including a complex generic) in Mainland China and/or other countries or regions

Acquired product rights of 11 generics (including a complex generic) in Mainland China and/or other countries or regions

  • About Us
    • CMS Overview
    • Leadership
    • Milestones
    • Social Responsibility
  • Innovation
    • R&D Overview
    • Pipeline
  • Business
    • Business Overview
    • Cardio-cerebrovascular and Gastroenterology
    • Dermatology and Medical Aesthetics
    • Ophthalmology
    • Southeast Asia Business
  • News
    • Company News
    • Partner News
  • Investors
    • Stock Infomation
    • Financial Highlights
    • Information Disclosure
    • Corporate Governance
    • Investor Communication
  • Privacy
  • Terms Of Use
All rights reserved by CMS Group 2001-2022 ERP of CMS Group
互联网药品信息服务资格证书编号:(粤)-非经营性-2021-0109| 粤ICP备18157737号| 粤公网安备 44030502003605号